The role of coagulopathy and blood transfusion in acute respiratory distress syndrome by Cornet, A.D.
Colofon
The role of coagulopathy and blood transfusion in acute respiratory distress syndrome 
Thesis, Vrije Universiteit Amsterdam, The Netherlands 
 
ISBN 978-94-6108-599-3 
 
Copyright © 2014 A.D. Cornet, Amsterdam, The Netherlands 
All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system or 
transmitted in any way or by any means, without written permission of the author. 
 
Cover: Sarah Wijzenbeek | www.sarahwijzenbeek.com
Layout: Nicole Nijhuis, Gildeprint, Enschede 
Printed by: Gildeprint, Enschede
Financial support by the Dutch Heart Foundation for the publication of this thesis is gratefully 
acknowledged.
VRIJE UNIVERSITEIT
The role of coagulopathy and blood transfusion in 
acute respiratory distress syndrome
ACADEMISCH PROEFSCHRIFT
ter verkrijging van de graad Doctor aan
de Vrije Universiteit Amsterdam,
op gezag van de rector magnificus
prof.dr. F.A. van der Duyn Schouten,
in het openbaar te verdedigen
ten overstaan van de promotiecommissie
van de Faculteit der Geneeskunde
op dinsdag 4 maart 2014 om 13.45 uur
in de aula van de universiteit,
De Boelelaan 1105
door
Alexander Daniël Cornet
geboren te Velsen
promotoren: prof.dr. A.B.J. Groeneveld
 prof.dr. A.R.J. Girbes
copromotor: dr. A. Beishuizen
“Success is the ability to go from one failure to another
with no loss of enthousiasm.”
Winston Churchill
“Not everything that counts can be counted, 
and not everything that can be counted counts.”
Albert Einstein
Voor Lorraine
Overige leden promotiecommissie: prof. dr. M. Singer
 prof. dr. J.G. van der Hoeven
 prof. dr. M.J. Schultz
 prof. dr. A. Brand
 prof. dr. Y.M. Smulders
 prof. dr. A.A. van de Loosdrecht
 dr. N.P. Juffermans
Contents
Part I - IntroduCtIon
Chapter 1 General introduction and outline of the thesis 11
Chapter 2 The role of heparin and allied compounds in the treatment of sepsis 21
 Thromb Haemost 2007;98:579-586 
Chapter 3 Activated protein C in the treatment of acute lung injury and acute  39
 respriratory distress syndrome 
 Expert Opin Drug Discov 2009;4:219-227 
Part II – PreClInICal studIes
Chapter 4 Nebulized antithrombin limits bacterial outgrowth and lung injury in 59
 Streptococcus pneumoniae pneumonia in rats 
 Crit Care 2009;13:R145 
Chapter 5 Nebulized anticoagulants limit coagulopathy but not inflammation in  77 
 Pseudomonas aeruginosa-induced pneumonia in rats 
 Shock 2011;36:347-423 
Chapter 6 Nebulized fibrinolytic agents improve pulmonary fibrinolysis but not  91
 inflammation in rat models of direct and indirect acute lung injury. 
 PLoS One 2013;8:e55262 
 
Part III – ClInICal studIes
Chapter 7 Activated protein C attenuates pulmonary coagulopathy in patients with  109
 acute respiratory distress syndrome 
 J Thromb Haemost 2013;11:894-901 
Chapter 8 Randomized clinical trial of activated protein C for the treatment of  123
 patients with acute respiratory distress syndrome 
 Submitted 
Chapter 9 Pulmonary effects of red blood cell transfusion in critically ill,  141
 non-bleeding patients 
 Transfusion Medicine 2010;20:221-226 
Chapter 10 The effect of blood transfusion on pulmonary permeability in cardiac  153
 surgery patients: a prospective multicenter cohort study 
 Transfusion 2012;52:82-90 
 
Part IV – General dIsCussIon
Chapter 11 Summary and general discussion 171
Chapter 12 Nederlandse samenvatting voor niet-ingewijden 181
Part V – aPPendICes
 Bibliography 195
 Curriculum vitae 199
 Acknowledgements 201
Part I
IntroductIon

1
General introduction
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
12  |  Chapter 1
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
General introduction |  13
1
General IntroduCtIon
Acute respiratory distress syndrome (ARDS), with its mildest form previously known as acute lung 
injury (ALI), occurs at rates between 30 and 80 per 100,000 person years and carries in-hospital 
mortality rates up to 40% [1,2]. It is an important contributor to the total amount of intensive 
care admissions. ARDS is a clinical syndrome that affects both medical and surgical patients [3]. 
 Recently, the definition of ARDS has been updated: the Berlin definition. This definition states 
that symptoms occur within 1 week of a clinical insult known to exasperate ARDS; on chest 
imaging there are bilateral opacities; respiratory failure cannot be explained by cardiac failure or 
fluid overload; there is an oxygenation impairment defined by a partial arterial oxygen pressure / 
fraction of inspired oxygen (PaO2/FIO2) ≤ 300. There are three degrees of ARDS severity based on 
the degree of oxygen impairment: mild (200 mmHg < PaO2/FIO2≤ 300 mmHg), moderate (100 
mmHg < PaO2/FIO2 ≤ 200 mmHg) and severe (PaO2/FIO2 ≤ 100 mmHg)[4]. 
Major risk factors for ARDS include direct pulmonary injury, such as pneumonia, aspiration of 
toxic compounds and indirect injury such as sepsis or wide-spread inflammatory responses to 
(ischemic) tissue damage [5]. During this inflammatory reaction, leukocytes (neutrophils) are 
recruited and adherence to the pulmonary vascular endothelium follows in order to permeate 
the vessel wall and penetrate the tissues. Accrued neutrophils in the injured lung in turn lead 
to enhanced production of pro-inflammatory cytokines and increased expression of adhesion 
molecules. These recruited neutrophils actually damage both the vascular endothelium, and 
the alveolar epithelium, compromising its natural barrier function and incapacitating its role 
in removing alveolar edema fluid [6]. Thus, alveolocapillary inflammation and disruption of 
endothelium, all leading to barrier dysfunction and increased permeability resulting in pulmonary 
edema, are hallmarks of the pathogenesis of ARDS [7-9].
Pulmonary leak Index
Frequently, it can be difficult to distinguish between cardiogenic (hydrostatic) edema and edema 
caused by increased pulmonary vascular permeability as a result of ARDS. The pulmonary leak 
index (PLI) is a bed-side radionuclide measurement which can be used to discriminate between 
the aforementioned types of edema. Transferrin is labeled in vivo with 67Gallium-citrate and with 
two scintillation probes (one for each lung) radioactivity can be measured [10]. Simultaneously, 
radioactivity in blood samples is measured. A radioactivity ratio (lung/blood) can then be calculated 
and the PLI will be derived from the change in ratio over time. The PLI reflects protein transport 
from the intra- to the extravascular space of the lungs as a direct measure of pulmonary vascular 
permeability [11].
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Crosstalk between InflammatIon and CoaGulatIon
As described above, development of ARDS is associated with pulmonary release and production 
of pro- and anti-inflammatory mediators [12]. Pro-inflammatory cytokines, such as interleukin 
(IL) -1 and 6, as well as tumor necrosis factor (TNF)-a, activate the coagulation cascade via tissue 
factor (TF) and attenuate fibrinolysis through activation of plasminogen activator inhibitor (PAI)-1, 
the main inhibitor of fibrinolysis [13]. 
CoaGulatIon and natural antICoaGulants
Activation of coagulation is regulated by three anticoagulant pathways: antithrombin (AT), the 
protein C (PC) system and tissue factor pathway inhibitor (TFPI). During inflammation-induced 
activation of coagulation, impairment of all three systems may occur, due to consumption and 
depletion of individual anticoagulants [14]. 
Firstly, AT is a serine protease inhibitor, which is synthesized in the liver, and is the main inhibitor 
of thrombin and factor Xa. During severe inflammatory states, levels of AT are clearly reduced, 
which is the resultant of consumption (due to ongoing thrombin generation), impaired synthesis 
(due to negative acute phase response) and degradation by elastase, released from activated 
neutrophils [15]. 
Secondly, the inactive precursor of the serine protease activated protein C (APC) is protein C (PC). 
The conversion from PC to APC occurs when thrombin binds to thrombomodulin, expressed 
on the endothelial surface. Together with the co-factor protein S, APC irreversibly inactivates 
factors Va and VIIIa, which play a critical role in the coagulation cascade. In addition, APC has 
anticoagulant properties by reducing TF expression on monocytes and exerts direct profibrinolytic 
activity due to neutralization of plasminogen activator inhibitor (PAI) -1 activity and indirectly to 
a decrease in thrombin-activatable fibrinolysis inhibitor (TAFI) as a result of decreased thrombin 
formation by its anticoagulant activity [16]. During severe inflammation, PC (and APC) levels 
are decreased due to impaired synthesis and degradation by neutrophil elastase. Additionally, 
thrombomodulin is downregulated at the endothelial surface, mediated by TNF-a and IL-1b [15]. 
Thirdly, TFPI is the main inhibitor of the TF-factor VIIa complex. However, in states of severe 
inflammation, TFPI is overwhelmed by increased expression of TF [17]. Central elements in the 
pathogenesis of ARDS are concomitant activation of coagulation and inflammation, together 
with inhibition of fibrinolysis, resulting in barrier dysfunction and increased alveolocapillary 
permeability. This coagulopathy may offer an opportunity for pharmacological intervention, since 
treatment of ARDS still consists only of supportive measures and is directed at avoiding additional 
harm by mechanical ventilation.
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InterVentIons wIth antICoaGulants In ards
Activation of coagulation and inhibition of fibrinolysis are the corner stones in the pathophysiology 
of both sepsis and ARDS. Three major phase III trials (KyberSept [18], PROWESS [19], OPTIMIST 
[20]) have been conducted to evaluate the efficacy and safety of the three naturally occurring 
anticoagulants in patients with severe sepsis. Only the PROWESS trial (comparing recombinant 
human APC with placebo) was able to demonstrate a statistically significant reduction of the 
absolute mortality rate by 6.1% [19], although this was offset by the more recent PROWESS-
SHOCK trial [21]. Of note, post hoc analyses of the PROWESS trial results suggested that 
patients with severe community-acquired pneumonia (CAP), had faster resolution of pulmonary 
dysfunction and increased survival when treated with APC, resulting in a relative risk reduction in 
mortality of 28% at 28 days, and of 14% observed at 90 days from the start of study drug infusion 
[22]. The survival benefit was most distinct in CAP patients in whom Streptococcus pneumoniae 
was isolated, and in those patients at high risk of death, indicated either by an APACHE II score 
≥ 25 or a pneumonia severity index ≥ 4 [22]. Until now, there is only one randomized clinical 
trial evaluating APC in the treatment of ALI. Patients were randomized to receive either APC or 
placebo within 72 hrs after the onset of ALI, and APC did not seem to improve outcome [23]. 
However, this negative trial does not preclude a potential role for APC in the treatment of ALI. 
Enrolment may have been too early or too late, the number of patients enrolled may have been 
too small (n=75) and sepsis-induced ALI patients were excluded, despite the fact that these were 
exactly the patients who seemed to benefit most from APC in the PROWESS trial. 
loCal or systemIC treatment
The coagulopathy that ensues in ARDS is, at least primarily, a process that is localized within 
the lung. This has been demonstrated in patients with ventilator-associated pneumonia and in 
healthy volunteers who were exposed to intratracheal LPS [24,25]. Achieving high pulmonary 
concentrations of an anticoagulant may be essential to counter pulmonary coagulopathy. Possibly 
higher concentrations are needed, than can be realized by systemic (intravenous) administration. 
Nebulization and subsequent inhalation (and therefore local administration) of anticoagulants may 
result in higher pulmonary concentrations. Another potential benefit may be a reduction in the 
number of bleeding complications, as higher dosages of systemically administered anticoagulants 
or more likely to result in such complications.
blood transfusIon
Transfusion of blood products occurs frequently in critically ill patients, even when they are not 
bleeding [26,27]. However, transfusion may result in adverse effects. One of the most serious 
effects is the development of transfusion-related acute lung injury (TRALI) [28]. A widely 
accepted hypothesis for the pathogenesis of TRALI is the so-called “two hit model”. The “first 
hit” consists of the clinical condition of the patient at the time of transfusion. Neutrophils are 
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attracted to the pulmonary endothelium by an inflammatory reaction, where they get trapped in 
the microvasculature and become functionally hyperactive. The “second hit” is the transfusion. 
Bioactive substances or cytokines that have accumulated during storage further activate the 
already hyperactive neutrophils, with subsequent endothelial damage and pulmonary capillary 
leakage [29]. A well-known risk factor for developing TRALI is surgery, coronary bypass surgery 
in particular [30]. Hence, as in ARDS, TRALI is thought to be the result of increased permeability 
of pulmonary endothelium, edema formation and ultimately hypoxemia due to ventilation to 
perfusion mismatching.
outlIne of the thesIs
The first part of this thesis serves as an introduction to the concept of coagulation activation in 
different types of life-threatening conditions and the promising potential of anticoagulants as 
treatment modalities. In Chapter 2 we discuss the role of heparin and related compounds in 
the treatment of sepsis. The properties of heparin as a chemical compound, anticoagulant and 
anti-inflammatory drug are addressed, in vitro, in animal experiments and human studies. In 
Chapter 3 we investigate the possibilities for the use of APC in the treatment of ARDS. Not only 
the anticoagulant, profibrinolytic, anti-inflammatory and anti-apoptopic properties of APC are 
reviewed, but also its role in endothelial barrier enhancement. Additionally, the effects of APC in 
animal models of ARDS and clinical studies on ARDS are discussed. 
The second part comprises preclinical studies in which the effects of locally administered (i.e. 
nebulized) anticoagulant or profibrinolytic drugs are evaluated in rat models. Chapters 4 and 5 
report on studies in which lung injury was induced by intratracheal Streptococcus pneumoniae and 
Pseudomonas aeruginosa, respectively. Various anticoagulants were administered via nebulization 
and compared to placebo. In Chapter 6 the results of nebulization of different fibrinolytic agents 
in Pseudomonas aeruginosa pneumonia are discussed. In all three aforementioned studies, we 
hypothesized that nebulization of anticoagulant and fibrinolytic agents would result in reduced 
pulmonary coagulopathy as well as decreased pulmonary inflammation. 
The third part covers clinical studies. Chapters 7 and 8 address the results of the INFALI (Infectious 
of inflammatory acute lung injury (ALI) / ARDS) trial. In this open-label, non-blinded, randomized 
controlled multicenter trial, we hypothesized that infusion of recombinant human (rh) APC would 
attenuate increased pulmonary vascular permeability and thus benefit patients with ARDS as a 
single organ failure. INFALI was designed for single-organ failure, as rh-APC was at that time 
indicated for patients with severe sepsis and septic shock [31]. In chapter 7 we focus on the 
effects of rh-APC infusion on pulmonary coagulopathy, whereas chapter 8 encompasses clinical 
outcome as a whole, and changes in pulmonary vascular permeability in particular. Chapter 
9 is a retrospective chart analysis, in which we evaluated the effects of red blood cell (RBC) 
transfusions on several pulmonary parameters in critically ill patients, without overt bleeding. 
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We hypothesized that RBC transfusions induce subtle pulmonary changes, similar to sub-clinical 
TRALI, which may go unseen and therefore unreported. In Chapter 10 we report the results of a 
prospective multicenter cohort study. In this study we investigated the effect of blood transfusion 
on pulmonary permeability in patient who underwent cardiac surgery. Our hypothesis was that 
there would be a correlation between transfusion and leakage of the pulmonary vasculature.
In the general discussion the results of the studies described above are summarized and discussed 
and future directives are provided. 
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